Evidence map›Paper›PMID 41826883›Full record

ArticleBMC infectious diseases2026

Viral load suppression and associated factors among patients receiving ART in Mekelle, Ethiopia: a cross-sectional study.

Hadas Gebreyohannes, Mache Tsadik, Meseret Abay Fisseha, Mamit Gebreslassie Gebrekidan

Abstract read
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hadas GebreyohannesTigray Regional health office, Mekelle, Ethiopia.
Mache TsadikDepartment of Reproductive Health, School of Public Health, Mekelle University, Mekelle, Ethiopia.
Meseret Abay FissehaDepartment of Reproductive Health, School of Public Health, Mekelle University, Mekelle, Ethiopia. mesiabay@gmail.com.
Mamit Gebreslassie GebrekidanDepartment of Reproductive Health, School of Public Health, Mekelle University, Mekelle, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA significant number of individuals living with HIV are currently receiving combined antiretroviral therapy (cART), which is a combination of three or more antiretroviral medications used to treat HIV, with the goal of achieving viral suppression. However, little is known about the virological status of patients in Ethiopia, particularly in Mekelle, and the factors influencing viral load in this region have not been well studied. Therefore, this study aimed to assess the magnitude of viral load suppression and identify factors influencing it among patients attending ART care.

methodsA facility-based cross-sectional study was conducted in Mekelle City in March 2018. The study population included adult patients receiving cART, at public health facilities in Mekelle. A sample size of 456 was calculated using the double population proportion formula. A stratified systematic random sampling technique was used to select participants, and both primary and secondary data were collected. In the first step, the total number of patients on cART from October 1995 to March 1, 2017, was determined for each selected health facility. Patients who had been on cART for more than one year and met the inclusion criteria were identified. Proportional-to- population -size (PPS) sampling was then used to allocate the sample size across the health facilities. The first participant was selected randomly based on appointment numbers in the logbook, and the remaining participants were chosen at regular intervals (K = 4) from each facility. Variables with a p-value ≤ 0.20 in the bivariate analysis were included in the multivariable logistic regression model. Statistical significance in the multivariable analysis was set at p < 0.05. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs).

resultsA total of 456 eligible HIV-infected patients on cART were identified from medical records. Of these, 452 consented to participate in the interview, yielding a response rate of 99.1%. The viral load suppression rate was 86.7%. Factors significantly associated with lower odds of viral load suppression included being younger than 40 years (AOR = 0.30; 95% CI: 0.14–0.62), having an adherence rate below 95% (AOR = 0.21; 95% CI: 0.08–0.52), daily alcohol use (AOR = 0.12; 95% CI: 0.04–0.33), and a CD4 count of 0-199 cells/mm³ (AOR = 0.12; 95% CI: 0.04–0.39). Conversely, factors that increased the likelihood of viral load suppression included having at least a secondary education (AOR = 6.65; 95% CI: 2.26–19.58) and being on a single-tablet regimen (AOR = 4.87; 95% CI: 1.43–16.59).

conclusionThis study demonstrated a high viral load suppression rate (86.7%) among HIV-infected patients receiving cART, indicating generally effective treatment outcomes within the study population. However, viral suppression was significantly lower among patients younger than 40 years, those with suboptimal adherence (< 95%), daily alcohol users, and individuals with advanced immunosuppression (CD4 count 0–199 cells/mm³). Conversely, patients with at least secondary education and those receiving a single-tablet regimen were significantly more likely to achieve viral load suppression, underscoring the importance of educational empowerment and simplified treatment regimens in improving treatment success. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Anti-HIV AgentsHIV InfectionsViral LoadAdolescentAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCross-Sectional StudiesEthiopiaFemaleHumansMaleMiddle AgedYoung AdultAnti-HIV AgentsART CareEthiopiaMekelleSuppressionViral load

Identifiers

PMID41826883
PMCPMC13097658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.